A phase IIIb, multicenter, global, interventional, open-label study of trastuzumab deruxtecan (T-DXd), an anti-HER2 antibody-drug conjugate (ADC), in subjects with unresectable and/or metastatic HER2-low or immunohistochemical (IHC) HER2 0 breast cancer (BC)
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: DAIICHI-SANKYO, INC.
- Phase: III
- Execution start: 21/11/2023
- End of execution: 20/05/2028
- IP: ENCARNA GONZALEZ FLORES
